This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

David's Most Recent Article

Gilead Buying Vertex Among Bold Biotech Stock Predictions for 2015

01/09/15 - 10:42 AM EST

The 2015 biotech stock predictions of TheStreet contributor David Sobek.

read more >

Other Articles by David

Free Reports

2014 Healthcare Stock Report Card: Sobek Tracks His Hits and Misses 2014 Healthcare Stock Report Card: Sobek Tracks His Hits and Misses

12/18/14 - 09:35 AM EST

Gilead, Sangamo and Bluebird were great calls, Alexion and Vertex not so much.

read more >
Foundation Medicine Winning Increased Insurance Coverage for Genetic Cancer Tests Foundation Medicine Winning Increased Insurance Coverage for Genetic Cancer Tests

11/19/14 - 11:17 AM EST

Coverage decisions are still likely to slowly build over time but it is a clear positive that we are seeing the early adopters start to reimburse for Foundation's cancer tests.

read more >
Strong Prostate Cancer Drug Sales Will Help Medivation Expand Pipeline Strong Prostate Cancer Drug Sales Will Help Medivation Expand Pipeline

11/05/14 - 08:00 AM EST

The diversification away from Xtandi has only just begun.

read more >
Stock Weakness in Seattle Genetics, Gilead Sciences Belies Fundamental Strengths Stock Weakness in Seattle Genetics, Gilead Sciences Belies Fundamental Strengths

10/15/14 - 09:35 AM EDT

Some perspective on recent positive news, which nonetheless, caused Seattle Genetics and Gilead shares to fall.

read more >
Acceleron Hit Over Competitive Concerns, but Investors Overlook Rest of Pipeline Acceleron Hit Over Competitive Concerns, but Investors Overlook Rest of Pipeline

10/02/14 - 09:21 AM EDT

An Acceleron update in December could reignite investor interest in the stock.

read more >
Safety Worries Over Celgene's Experimental Crohn's Drug Overblown Safety Worries Over Celgene's Experimental Crohn's Drug Overblown

09/17/14 - 08:26 AM EDT

The first public presentation of the GED-031 phase II data will be on Oct. 21 at a European medical conference.

read more >
Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity

09/10/14 - 09:36 AM EDT

The Ebola outbreak in West Africa is a public health emergency which has also captured the attention of U.S. investors (perhaps I should say traders.)

read more >
Tetraphase Oral Antibiotic Data Look Good Tetraphase Oral Antibiotic Data Look Good

09/03/14 - 06:30 AM EDT

Tetraphase is on track to begin second portion of pivotal study in the fourth quarter.

read more >
Previewing Tetraphase Oral Antibiotic Study Results Previewing Tetraphase Oral Antibiotic Study Results

08/27/14 - 08:00 AM EDT

Tetraphase will report data from a phase III study of eravacycline in which the experimental antibiotic is first given by intravenous infusion and then transitioned to an oral form.

read more >
Page 1 of 6
< Previous
Top Rated Stocks Top Rated Funds Top Rated ETFs